Dry Eye Syndrome Models

APPLICATIONS:

  • Dry eye syndrome (DES), dry eye disease (DED)
  • Keratoconjunctivitis sicca (KCS)

 

PRECLINICAL EFFICACY MODELS:

  • Extraorbital lacrimal gland excision
  • Scopolamine-induced dry eye syndrome
  • Controlled-environmental conditions and scopolamine-induced dry eye syndrome

 

EXAMPLE OF EVALUATIONS:

  • Superficial punctate keratitis (slit lamp examination)
  • Tear secretion (phenol red threat (PRT) tear test)
  • Histology analysis
  • Bioassays (eg. RT-qPCR, multiplex assay, ELISA)

 

PUBLICATIONS:

  • Modulation of inflammation-related genes in the cornea of a mouse model of dry eye upon treatment with cyclosporine eye drops. DAULL P et al. Curr. Eye Res. 2019 Jan 21:1-10. doi: 10.1080/02713683.2018.1563197 Article
  • Efficacy of preservative-free cyclosporine emulsion eye drops in a mouse model of dry eye. DAULL P et al. ARVO meeting 2019; Vancouver - Canada. Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):292. doi:  Poster
  • Dry Eye: Efficacy evaluation of two synthetic peptides from Chondrocyte Derived ExtraCellular Matrix (CDEM) in comparison to lifitegrast, cyclosporine A, diquafosol sodium and sodium hyaluronate in a murine model of dry eye.BAIK T et al. ARVO meeting 2019; Vancouver - Canada. Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):291. doi: Abstract
  • Comparison of inflammatory gene networks in dry eye between human and mouse. KESSAL K et al. ARVO meeting 2019; Vancouver - Canada. Abstract No. 274 - B0413 Abstract
  • Safety and tolerability of overdosed artificial tears by abraded rabbit corneas. DAULL P et al. J. Ocul. Pharmacol. Ther. 2018; DOI: 10.1089/jop.2018.0040 Abstract
  • Comparative efficacy of preservative-free anti-inflammatory eye drops in a mouse model of dry eye. GARRIGUE JS et al. ARVO meeting 2017; Baltimore - USA. Invest. Ophthalmol. Vis. Sci. 2017; 58(8):800. doi: Abstract
  • Corneal transcriptome changes in a mouse model of dry eye. DAULL P et al. ARVO meeting 2017; Baltimore - USA. Invest. Ophthalmol. Vis. Sci. 2017; 58(8):797. doi: Abstract
  • Efficacy of a new topical cationic emulsion of cyclosporine A on dry eye clinical signs in an experimental mouse model of dry eye. DAULL P et al. Exp. Eye Res. 2016 Oct 21; 153:159-164 Article
  • Comparative efficacy of cyclosporine eye drop formulations in a mouse model of dry eye. GARRIGUE JS et al. ARVO meeting 2016; Seattle - USA. Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):421. doi: Poster
  • Efficacy of a preservative-free cationic emulsion vehicle eye drop in a mouse model of dry eye. QUENTRIC Y et al. ARVO meeting 2016; Seattle - USA. Invest. Ophthalmol. Vis. Sci. Sept. 2016, Vol.57, 422. doi: Poster
  • HL036337 ophthalmic solution: topical TNF blocker for dry eye disease. Protein and AntiboPEGS meeting 2015 Boston, MA (collaboration)
  • Evaluation of a cyclosporine A ophthalmic ointment in an experimental mouse model of dry eye. CIMBOLINI N et al. EVER meeting 2015; Nice – France. Poster T031 Poster
  • Efficacy evaluation of a cationic emulsion of cyclosporine in a mouse model of dry eye. DAULL P et al. ARVO meeting 2015; Denver, CO - USA. Invest. Ophthalmol. Vis. Sci. June 2015, Vol.56, 4468. doi: Abstract
  • The effect of preservatives and antiglaucoma treatments on the ocular surface of mice with dry eye. BARABINO S et al. Invest. Ophthalmol. Vis. Sci. 2014; 55:6499-6504 doi:10.1167/iovs.14-14548 Article
  • Dry eye: two experimental rodent models for drug development. CIMBOLINI N et al.TFOS meeting 2013; Taormina - Sicily – Italy Poster
  • Effects of cyclosporine in an experimental rat model of dry eye. CIMBOLINI N et al. EVER meeting 2013; Nice – France. Poster S008 Poster
  • Impact of the routes of administration on the effects of cyclosporine in an experimental rat model of dry eye. CIMBOLINI N et al. ISOPT meeting 2013; Paris – France Poster
  • Comparison of two rodent models of dry eye induced by scopolamine. ELENA PP et al. ARVO meeting 2013; Seattle, WA - USA. ARVO e-abstract No. 6002 - Poster A0065 Abstract
  • Cationic oil-in-water emulsion as an improved cyclosporine ocular vehicle for vernal keratoconjuctivitis sicca (VKC). LAMBERT G et al. ARVO meeting 2007; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 2007, Vol.48, 2301. doi: (collaboration) Abstract
  • Potency and duration of action of synthetic P2Y2 receptor agonists on schirmer scores in rabbits. YERXA BR et al. Adv. Exp. Med. Biol. 2002; 506: 261-265 Abstract
  • Potency and duration of action of synthetic P2Y2-receptor agonists on schirmer scores in rabbits. YERXA BR et al. 3rd International Conference on the Lacrimal Gland, Tear Film and Dry Eye Syndromes Maui, HI – USA - Cornea 2000; 19: S138
  • INS365, a P2Y2 receptor agonist, increases schirmer scores in albino rabbits. YERXA BR et al. ARVO meeting 1999; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1999; 40: S540, abstract No. 2848
  • Topical sodium sucrose octasulphate reduces corneal lesions in a keratoconjunctivitis sicca model in the rat. CHIBRET H et al. ARVO meeting 1994; Sarasota, FL - USA. Invest. Ophthalmol. Vis. Sci. 1994; 35: 1693, abstract No. 2039